Multiple action agents and the eye: Do they really stabilize mast cells?

Current Opinion in Allergy and Clinical Immunology

Volumn 9, Issue 5, 2009, Pages 454-465

  Lambiase, Alessandro ^a   Micera, Alessandra ^a,b   Bonini, Stefano ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Azelastine; Epinastine; Ketotifen; Mast cells; Olopatadine

Indexed keywords

AMLEXANOX; ANTAZOLINE; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; AZELASTINE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CLEMASTINE; CROMOGLYCATE DISODIUM; DESLORATADINE; DEXAMETHASONE; DIPHENHYDRAMINE; EMEDASTINE; EPINASTINE; HISTAMINE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; KETOTIFEN; LEVOCABASTINE; LORATADINE; MEPYRAMINE; NEDOCROMIL; OLOPATADINE; PHENIRAMINE; RANITIDINE; SPAGLUMIC ACID; TERFENADINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALLERGIC CONJUNCTIVITIS; ANTIINFLAMMATORY ACTIVITY; ASTHMA; ATOPIC DERMATITIS; CALCIUM CELL LEVEL; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DEGRANULATION; DRUG EFFECT; FOOD ALLERGY; HAY FEVER; HISTAMINE RELEASE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MAST CELL; NONHUMAN; PERENNIAL RHINITIS; PRIORITY JOURNAL; REVIEW; URTICARIA;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARACHIDONIC ACID; CONJUNCTIVITIS, ALLERGIC; CYTOKINES; DIBENZAZEPINES; DIBENZOXEPINS; HISTAMINE; HISTAMINE ANTAGONISTS; HUMANS; IMIDAZOLES; IMMUNITY, INNATE; KETOTIFEN; MAST CELLS; PHTHALAZINES;

EID: 69749121407     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0b013e3283303ebb     Document Type: Review

References (100)

1. Bielory L. Allergic and immunologic disorders of the eye. Part I: immunology of the eye. J Allergy Clin Immunol 2000; 106:805-816. (Pubitemid 30949041)
2. Tsubota K, Takamura E, Hasegawa T, Kobayashi T. Detection by brush cytology of mast cells and eosinophils in allergic and vernal conjunctivitis. Cornea 1991; 10:525-531.
3. Irani AM, Butrus SI, Tabbara KF, Schwartz LB. Human conjunctival mast cells: distribution of MCT and MCTC in vernal conjunctivitis and giant papillary conjunctivitis. J Allergy Clin Immunol 1990; 86:34-40.
4. Leonardi A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs 2005; 10:505-520.
5. Leonardi A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol Scand 2000; 78 (Suppl):18-21.
6. Woodward DF, Hawley SB, Williams LS, et al. Studies on the ocular pharmacology of prostaglandin D2. Invest Ophthalmol Vis Sci 1990; 31:138-146.
7. Lippert U, Moller A, Welker P, et al. Inhibition of cytokine secretion from human leukemic mast cells and basophils by H1- and H2-receptor antagonists. Exp Dermatol 2000; 9:118-124. (Pubitemid 30192709)
8. Bielory L. Ocular allergy guidelines: a practical treatment algorithm. Drugs 2002; 62:1611-1634. (Pubitemid 34848369)
9. Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005; 65:215-228. (Pubitemid 40139383)
10. Kempuraj D, Huang M, Kandere-Grzybowska K, et al. Azelastine inhibits secretion of IL-6, TNF-alpha and IL-8 as well as NF-kappaB activation and intracellular calcium ion levels in normal human mast cells. Int Arch Allergy Immunol 2003; 132:231-239.
11. Saito H, Ebisawa M, Tachimoto H, et al. Selective growth of human mast cells induced by Steel factor, IL-6, and prostaglandin E2 from cord blood mononuclear cells. J Immunol 1996; 157:343-350. (Pubitemid 26190566)
12. Kimata M, Shichijo M, Miura T, et al. Ca2+ and protein kinase C signaling for histamine and sulfidoleukotrienes released from human cultured mast cells. Biochem Biophys Res Commun 1999; 257:895-900. (Pubitemid 29301539)
13. Kimata M, Inagaki N, Nagai H. Effects of luteolin and other flavonoids on IgEmediated allergic reactions. Planta Med 2000; 66:25-29. (Pubitemid 30097275)
14. Douglas WW. Involvement of calcium in exocytosis and the exocytosis-vesiculation sequence. Biochem Soc Symp 1974; 39:1-28.
15. Schwartz LB, Lewis RA, Seldin D, Austen KF. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. J Immunol 1981; 126:1290-1294. (Pubitemid 11149212)
16. Kempuraj D, Huang M, Kandere K, et al. Azelastine is more potent than olopatadine n inhibiting interleukin-6 and tryptase release from human umbilical cord blood-derived cultured mast cells. Ann Allergy Asthma Immunol 2002; 88:501-506. (Pubitemid 36182009)
17. Lytinas M, Kempuraj D, Huang M, et al. Azelastine's inhibition of histamine and tryptase release from human umbilical cord blood-derived cultured mast cells as well as rat skin mast cell-induced vascular permeability: comparison with olopatadine. Allergy Asthma Proc 2002; 23:45-51.
18. Shichijo M, Inagaki N, Nakai N, et al. The effects of antiasthma drugs on mediator release from cultured human mast cells. Clin Exp Allergy 1998; 28:1228-1236. (Pubitemid 29087013)
19. Saito T, Hagihara A, Igarashi N, et al. Inhibitory effects of emedastine difumarate on histamine release. Jpn J Pharmacol 1993; 62:137-143. (Pubitemid 23218232)
20. Asano K, Furuta A, Kanai K, et al. Inhibition of angiogenic factor production from murine mast cells by an antiallergic agent (epinastine hydrochloride) in vitro. Mediators Inflamm 2008; 2008:265095. In this study, the authors investigated the effects of the epinastine-mediated inhibition of the newly formed mediators responsible for the angiogenic effects observed upon mast cell activation.
21. Sharif NA, Xu SX, Miller ST, et al. Characterization of the ocular antiallergic and antihistaminic effects of olopatadine (AL-4943A), a novel drug for treating ocular allergic diseases. J Pharmacol Exp Ther 1996; 278:1252-1261.
22. Yanni JM, Miller ST, Gamache DA, et al. Comparative effects of topical ocular antiallergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997; 79:541-545.
23. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits TNFalpha release from human conjunctival mast cells. Ann Allergy Asthma Immunol 2000; 84:504-508. (Pubitemid 30365412)
24. Cook EB, Stahl JL, Barney NP, Graziano FM. Olopatadine inhibits antiimmunoglobulin E-stimulated conjunctival mast cell upregulation of ICAM-1 expression on conjunctival epithelial cells. Ann Allergy Asthma Immunol 2001; 87:424-429.
25. Galatowicz G, Ajayi Y, Stern ME, Calder VL. Ocular antiallergic compounds selectively inhibit human mast cell cytokines in vitro and conjunctival cell infiltration in vivo. Clin Exp Allergy 2007; 37:1648-1656. The authors of this article provide a well documented comparative study of the effects played by azelastine, olopatadine and epinastine in mediating both early and late-phase mast cell reactions. Particularly, human cord blood stem cell-derived and conjunctival biopsy-derived mast cells were induced to release histamine and to synthesize cytokines. All drugs significantly reduced histamine and TNF-a production/release, whereas IL5, IL8, IL10 and TNF-b were differentially decreased. (Pubitemid 47609843)
26. McTavish D, Sorkin EM. Azelastine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989; 38:778-800. (Pubitemid 19285393)
27. Chand N, Pillar J, Diamantis W, et al. Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by azelastine: implications for its mode of action. Eur J Pharmacol 1983; 96:227-233.
28. Chand N, Pillar J, Diamantis W, Sofia RD. Inhibition of IgE-mediated allergic histamine release from rat peritoneal mast cells by azelastine and selected antiallergic drugs. Agents Actions 1985; 16:318-322. (Pubitemid 15040971)
29. Fields DA, Pillar J, Diamantis W, et al. Inhibition by azelastine of nonallergic histamine release from rat peritoneal mast cells. J Allergy Clin Immunol 1984; 73:400-403. (Pubitemid 14164771)
30. Kurosawa M, Okayama Y, Kobayashi S. Inhibitory effect of adenine nucleotides and antiallergic drugs on phosphorylation of phosphatidylinositol in rat mast cell granules. Allergy 1989; 44:576-581. (Pubitemid 20005752)
31. Busse W, Randlev B, Sedgwick J. The effect of azelastine on neutrophil and eosinophil generation of superoxide. J Allergy Clin Immunol 1989; 83:400-405. (Pubitemid 19079733)
32. Sharif NA, Su SX, Yanni JM. Emedastine: a potent, high affinity histamine H1- receptor-selective antagonist for ocular use - receptor binding and second messenger studies. J Ocul Pharmacol 1994; 10:653-664.
33. el-Shazly AE, Masuyama K, Samejima Y, et al. Inhibition of human eosinophil chemotaxis in vitro by the antiallergic agent emedastine difumarate. Immunopharmacol Immunotoxicol 1996; 18:587-595.
34. Andoh T, Kuraishi Y. Involvement of blockade of leukotriene B(4) action in antipruritic effects of emedastine in mice. Eur J Pharmacol 2000; 406:149-152.
35. Kamei C, Akagi M, Mio M, et al. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions. (I): elucidation of the mechanism for histamine release inhibition. Immunopharmacol Immunotoxicol 1992; 14:191-205.
36. Klemm S, Ruland J. Inflammatory signal transduction from the Fc epsilon RI to NF-kappa B. Immunobiology 2006; 211:815-820. (Pubitemid 44734622)
37. Shin HY, Kim SH, Jeong HJ, et al. Epigallocatechin-3-gallate inhibits secretion of TNF-alpha, IL-6 and IL-8 through the attenuation of ERK and NFkappaB in HMC-1 cells. Int Arch Allergy Immunol 2007; 142:335-344.
38. Grant SM, Goa KL, Fitton A, Sorkin EM. Ketotifen: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma and allergic disorders. Drugs 1990; 40:412-448. (Pubitemid 20287934)
39. Schoch C. In vitro inhibition of human conjunctival mast-cell degranulation by ketotifen. J Ocul Pharmacol Ther 2003; 19:75-81.
40. Brockman H, Graff G, Spellman J, Yanni J. A comparison of the effects of olopatadine and ketotifen on model membranes. Acta Ophthalmol Scand 2000; 230 (Suppl):10-15.
41. Truneh A, White JR, Pearce FL. Effect of ketotifen and oxatomide on histamine secretion from mast cells. Agents Actions 1982; 12:206-209.
42. Brockman HL, Momsen MM, Knudtson JR, et al. Interactions of olopatadine and selected antihistamines with model and natural membranes. Ocul Immunol Inflamm 2003; 11:247-268.
43. Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and antihistamine effects of olopatadine ophthalmic solution: a review of preclinical and clinical research. Curr Med Res Opin 2005; 21:1377-1387. (Pubitemid 41368569)
44. Ohmori K, Hasegawa K, Tamura T, et al. Properties of olopatadine hydrochloride, a new antiallergic/antihistaminic drug. Arzneimittelforschung 2004; 54:809-829. (Pubitemid 39657678)
45. Ikemura T, Manabe H, Sasaki Y, et al. KW-4679, an antiallergic drug, inhibits the production of inflammatory lipids in human polymorphonuclear leukocytes and guinea pig eosinophils. Int Arch Allergy Immunol 1996; 110:57-63. (Pubitemid 26116034)
46. Matsubara M, Masaki S, Ohmori K, et al. Differential regulation of IL-4 expression and degranulation by antiallergic olopatadine in rat basophilic leukemia (RBL-2H3) cells. Biochem Pharmacol 2004; 67:1315-1326. (Pubitemid 38315097)
47. Corin RE. Nedocromil sodium: a review of the evidence for a dual mechanism of action. Clin Exp Allergy 2000; 30:461-468.
48. Gonzalez JP, Brogden RN. Nedocromil sodium: a preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the treatment of reversible obstructive airways disease. Drugs 1987; 34:560-577. (Pubitemid 17147673)
49. e Silva PM, Martins MA, Castro-Faria-Neto HC, et al. Nedocromil sodium prevents in vivo generation of the eosinophilotactic substance induced by PAF but fails to antagonize its effects. Br J Pharmacol 1992; 105:436-440.
50. Carolan EJ, Casale TB. Effects of nedocromil sodium and WEB 2086 on chemoattractant-stimulated neutrophil migration through cellular and noncellular barriers. Ann Allergy 1992; 69:323-328.
51. Diebold Y, Calonge M, Carretero V, et al. Expression of ICAM-1 and HLA-DR by human conjunctival epithelial cultured cells and modulation by nedocromil sodium. J Ocul Pharmacol Ther 1998; 14:517-531. (Pubitemid 28566793)
52. Hoyos L, Norris A, Vargaftig BB. Effects of nedocromil sodium on antigen-induced conjunctivitis in guinea pigs. Adv Ther 2000; 17:1-6. (Pubitemid 30180870)
53. Ahluwalia P, Anderson DF, Wilson SJ, et al. Nedocromil sodium and levocabastine reduce the symptoms of conjunctival allergen challenge by different mechanisms. J Allergy Clin Immunol 2001; 108:449-454. (Pubitemid 32881069)
54. Kamei C, Izushi K, Nakamura S. Effects of certain antiallergic drugs on experimental conjunctivitis in guinea pigs. Biol Pharm Bull 1995; 18:1518-1521.
55. Yanni JM, Stephens DJ, Parnell DW, Spellman JM. Preclinical efficacy of emedastine, a potent, selective histamine H1 antagonist for topical ocular use. J Ocul Pharmacol 1994; 10:665-675.
56. Kamei C, Sugimoto Y, Nakamura S, Zhong C. Effect of (Z)-11-[3- (dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid hydrochloride on experimental allergic conjunctivitis and rhinitis in rats and guinea pigs. Arzneimittelforschung 1995; 45:1005-1008.
57. Beauregard C, Stephens D, Roberts L, et al. Duration of action of topical antiallergy drugs in a Guinea pig model of histamine-induced conjunctival vascular permeability. J Ocul Pharmacol Ther 2007; 23:315-320. (Pubitemid 350195055)
58. Sanchis-Merino ME, Montero JA, Ruiz-Moreno JM, et al. Comparative efficacy of topical antihistamines in an animal model of early phase allergic conjunctivitis. Exp Eye Res 2008; 86:791-797. The authors show potential and comparative effects of topical antihistamines in an animal model of early-phase allergic conjunctivitis.
59. Chand N, Harrison JE, Rooney SM, et al. Inhibition of passive cutaneous anaphylaxis (PCA) by azelastine: dissociation of its antiallergic activities from antihistaminic and antiserotonin properties. Int J Immunopharmacol 1985; 7:833-838. (Pubitemid 16213250)
60. Shirasaki H, Asakura K, Sohma S, Kataura A. Inhibitory effects of azelastine on nasal allergic responses in sensitized guinea pigs. Eur Arch Otorhinolaryngol 1992; 249:279-282.
61. Satoh T, Tahara E, Yamada T, et al. Differential effect of antiallergic drugs on IgE-mediated cutaneous reaction in passively sensitized mice. Pharmacology 2000; 60:97-104. (Pubitemid 30098823)
62. Berger G, Berger R, Goldberg A. Ketotifen induced inhibition of histamine release in a non-IgE model of middle ear effusion. Pediatr Allergy Immunol 2006; 17:43-48.
63. Russo A, Russo G, Peticca M, et al. Inhibition of granuloma-associated angiogenesis by controlling mast cell mediator release: role of mast cell protease-5. Br J Pharmacol 2005; 145:24-33. (Pubitemid 40675545)
64. Kamei C, Izushi K, Adachi Y, et al. Inhibitory effect of epinastine on the type II-IV allergic reactions in mice, rats and guinea pigs. Arzneimittelforschung 1991; 41:1150-1153.
65. Inagaki N, Nagao M, Nakamura N, et al. Evaluation of antiscratch properties of oxatomide and epinastine in mice. Eur J Pharmacol 2000; 400:73-79. (Pubitemid 30412111)
66. Kaise T, Ohmori K, Sakakura Y, Ukai K. The effect of KW-4679, an antiallergic drug, on experimental allergic rhinitis in guinea pigs: effects on nasal blockage. Jpn J Pharmacol 1995; 69:435-438. (Pubitemid 26013778)
67. Howarth PH. Mediators of nasal blockage in allergic rhinitis. Allergy 1997; 52:12-18. (Pubitemid 27444751)
68. Ohmori K, Ishii H, Sasaki Y, et al. Effects of KW-4679, a new orally active antiallergic drug, on antigen-induced bronchial hyperresponsiveness, airway inflammation and immediate and late asthmatic responses in guinea pigs. Int Arch Allergy Immunol 1996; 110:64-72. (Pubitemid 26116035)
69. Miyake K, Horikoshi K, Ikeda Y, et al. Effects of olopatadine hydrochloride on the increase of histamine and peptide-leukotrienes concentrations in nasal lavage fluid following the antigen-antibody reaction in actively sensitized guinea pigs. Jpn J Pharmacol 2001; 85:453-456. (Pubitemid 32421737)
70. Canonica GW, Ciprandi G, Petzold U, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003; 19:321-329. (Pubitemid 36827841)
71. Friedlaender MH, Harris J, LaVallee N, et al. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology 2000; 107:2152-2157.
72. Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert antiallergic activity. Clin Exp Allergy 1997; 27:182-191. (Pubitemid 27085419)
73. Pipkorn P, Costantini C, Reynolds C, et al. The effects of the nasal antihistamines olopatadine and azelastine in nasal allergen provocation. Ann Allergy Asthma Immunol 2008; 101:82-89. (Pubitemid 352000749)
74. Hoshino M, Nakamura Y. The effect of azelastine on the infiltration of inflammatory cells into the bronchial mucosa and clinical changes in patients with bronchial asthma. Int Arch Allergy Immunol 1997; 114:285-292. (Pubitemid 27448444)
75. Zweiman B, Atkins PC, Moskovitz A, et al. Cellular inflammatory responses during immediate, developing, and established late-phase allergic cutaneous reactions: effects of cetirizine. J Allergy Clin Immunol 1997; 100:341-347. (Pubitemid 27402776)
76. Giede C, Metzenauer P, Petzold U, Ellers-Lenz B. Comparison of azelastine eye drops with levocabastine eye drops in the treatment of seasonal allergic conjunctivitis. Curr Med Res Opin 2000; 16:153-163. (Pubitemid 32054830)
77. Sabbah A, Marzetto M. Azelastine eye drops in the treatment of seasonal allergic conjunctivitis or rhinoconjunctivitis in young children. Curr Med Res Opin 1998; 14:161-170. (Pubitemid 28425159)
78. Orfeo V, Vardaro A, Lena P, et al. Comparison of emedastine 0.05% or nedocromil sodium 2% eye drops and placebo in controlling local reactions in subjects with allergic conjunctivitis. Eur J Ophthalmol 2002; 12:262-266.
79. Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 2000; 130:717-723. (Pubitemid 32000852)
80. Verin P, Easty DL, Secchi A, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol 2001; 131:691-698. (Pubitemid 32522637)
81. Secchi A, Ciprandi G, Leonardi A, et al. Safety and efficacy comparison of emedastine 0.05% ophthalmic solution compared to levocabastine 0.05% ophthalmic suspension in pediatric subjects with allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand 2000; 230 (Suppl):42-47.
82. Secchi A, Leonardi A, Discepola M, et al. An efficacy and tolerance comparison of emedastine difumarate 0.05% and levocabastine hydrochloride 0.05%: reducing chemosis and eyelid swelling in subjects with seasonal allergic conjunctivitis. Emadine Study Group. Acta Ophthalmol Scand 2000; (Suppl):48-51.
83. Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004; 26:35-47. (Pubitemid 38241521)
84. Whitcup SM, Bradford R, Lue J, et al. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis. Clin Ther 2004; 26:29-34. (Pubitemid 38241520)
85. Abelson MB, Chapin MJ, Kapik BM, Shams NB. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch Ophthalmol 2003; 121:626-630. (Pubitemid 36554464)
86. Torkildsen GL, Abelson MB, Gomes PJ. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis. Clin Ther 2008; 30:1272-1282.
87. Martin AP, Urrets-Zavalia J, Berra A, et al. The effect of ketotifen on inflammatory markers in allergic conjunctivitis: an open, uncontrolled study. BMC Ophthalmol 2003; 3:2. (Pubitemid 38789508)
88. Avunduk AM, Tekelioglu Y, Turk A, Akyol N. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivities: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin Ther 2005; 27:1392-1402. (Pubitemid 41598370)
89. Naclerio RM. The effect of antihistamines on the immediate allergic response: a comparative review. Otolaryngol Head Neck Surg 1993; 108:723-730.
90. Phillips MJ, Meyrick Thomas RH, Moodley I, Davies RJ. A comparison of the in vivo effects of ketotifen, clemastine, chlorpheniramine and sodium cromoglycate on histamine and allergen induced weals in human skin. Br J Clin Pharmacol 1983; 15:277-286. (Pubitemid 13137451)
91. Huston DP, Bressler RB, Kaliner M, et al. Prevention of mast-cell degranulation by ketotifen in patients with physical urticarias. Ann Intern Med 1986; 104:507-510. (Pubitemid 16137812)
92. Mallet AI, Norris P, Rendell NB, et al. The effect of disodium cromoglycate and ketotifen on the excretion of histamine and N tau-methylimidazole acetic acid in urine of patients with mastocytosis. Br J Clin Pharmacol 1989; 27:88-91. (Pubitemid 19037984)
93. Kidd M, McKenzie SH, Steven I, et al. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol 2003; 87:1206-1211. (Pubitemid 37193906)
94. Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial. Clin Ther 2003; 25:1975-1987.
95. Abelson MB. A review of olopatadine for the treatment of ocular allergy. Expert Opin Pharmacother 2004; 5:1979-1994. (Pubitemid 39236599)
96. Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998; 81:211-218.
97. Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am J Ophthalmol 1998; 125:797-804. (Pubitemid 28283741)
98. Leonardi A, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003; 25:2539-2552. (Pubitemid 37373929)
99. AbelsonMB, Greiner JV.Comparative efficacy of olopatadine 0.1%ophthalmic solution versus levocabastine 0.05% ophthalmic suspension using the conjunctival allergen challengemodel. CurrMed ResOpin 2004; 20:1953-1958.
100. Abelson MB, Lanier RQ. The added benefit of local Patanol therapy when combinedwithsystemic Claritin for theinhibitionofocular itching in theconjunctival antigen challenge model. Acta Ophthalmol Scand 1999; (Suppl):53-56.